XWXiaoxiao Wang

Xiaoxiao Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoxiao Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Shoudong Ye

    Center for Stem Cell and Translational Medicine School of Life Sciences and Medical Engineering Anhui University Hefei China

    4 shared publications
  • Wei Lu

    Center for Stem Cell and Translational Medicine, School of Life Sciences and Medical Engineering, Anhui University, Hefei, China

    2 shared publications
  • Xiangfen Li

    Center for Stem Cell and Translational Medicine, School of Life Sciences, Anhui University, Hefei, Anhui 230601, China

    2 shared publications
  • Yang Yu

    Center for Stem Cell and Translational Medicine, School of Life Sciences, Anhui University, Hefei, China

    2 shared publications
  • Yuting Li

    Center for Stem Cell and Translational Medicine, School of Life Sciences, Anhui University, Hefei, Anhui 230601, China

    2 shared publications
  • Bing Li

    Center for Stem Cell and Translational Medicine, School of Life Sciences, Anhui University, Hefei, Anhui 230601, China

    1 shared publication

Latest Publications

  • Open Access

    TFCP2L1 suppresses breast cancer progression by promoting ferroptosis through direct and PI3K/AKT-mediated inhibition of GPX4

    by Xiaoxiao Wang, Wei Lu, Yandi Cui, Keqiang He, Yuanzhi Bie, Shou-Dong Ye, Xiangfen Li

    Breast cancer is the most prevalent type of malignant tumor among women. Here, we identified transcription factor CP2-like 1 (TFCP2L1) as a suppressor of breast cancer cells. Patients with breast cancer have poorer prognoses when TFCP2L1 is expressed at low levels. Consistently, the expression of TFCP2L1 is greater in normal breast tissues and cells than in breast cancer tissues and cell lines. Gain- and loss-of-function experiments and xenograft tumor assays revealed that overexpression of TFCP2L1 significantly inhibited the proliferation and migration of breast cancer cells. Conversely, the knockdown of TFCP2L1 promoted the growth and migration of breast cancer cells. Mechanistically, TFCP2L1 suppresses breast cancer progression by inhibiting the expression of glutathione peroxidase 4 ( GPX4 ), a key positive regulator of ferroptosis. Therefore, the addition of a ferroptosis inhibitor, Ferrostatin-1, can mediate the function of TFCP2L1 in breast cancer cells. On the other hand, high-throughput transcriptome sequencing revealed that TFCP2L1 negatively regulates the activity of the PI3K/AKT signaling pathway. The administration of SC79, an AKT activator, partially reversed the negative effects of TFCP2L1 on GPX4 transcription. Together, these findings indicate that TFCP2L1 functions partially by directly and indirectly regulating GPX4 -mediated ferroptosis and may serve as a potential therapeutic target for breast cancer.


  • Open Access

    NCBP2 drives colorectal cancer growth and metastasis through LIPG-mediated lipid droplet accumulation

    by Liu Liu, Wei Lu, Shengyuan Miao, Yang Yu, Xu-Bing Zhang, ShouDong Ye, Xiaoxiao Wang, Lin Liu

    RNA-binding proteins play critical roles in RNA processing and are aberrantly expressed in colorectal cancer (CRC). Through comprehensive analysis of multiple gene expression datasets (GSE20916, GSE18105, GSE21510, TCGA-COAD and TCGA-READ), NCBP2 was identified as a potential tumorigenic gene in CRC. NCBP2 expression was significantly elevated in CRC tissues, correlated with tumour invasion and metastasis, and associated with poor patient survival outcomes. Furthermore, overexpression of NCBP2 in CRC cells was shown to increase cell proliferation, migration, and tumour invasion in both in vitro and in vivo models. Mechanistically, the NCBP2 protein stabilised LIPG mRNA via direct binding to the m7G motif in the 5’-cap structure of LIPG mRNA, thereby increasing LIPG expression. Additionally, NCBP2 promoted lipid droplet accumulation in CRC cells in a LIPG-dependent manner. These findings collectively suggest that the NCBP2-LIPG-lipid droplet axis represents a novel mechanism underlying CRC progression and metastasis, providing a promising therapeutic target for CRC treatment.


  • Open Access

    Prdm14 promotes mouse ESC self-renewal and PGCLC specification through enhancement of Stat3 activity

    by Yuting Li, Ziqiong Yang, Xiangfen Li, Yang Yu, Xiaofeng Li, Peng Chen, Bing Li, Xiaoxiao Wang, Shou-Dong Ye


  • Open Access

    Gadd45g initiates embryonic stem cell differentiation and inhibits breast cell carcinogenesis

    by Xinbao Zhang, Yuting Li, Junxiang Ji, Xin Wang, Meng Zhang, Xiangfen Li, Yan Zhang, Zhenhua Zhu, Shou-Dong Ye, Xiaoxiao Wang

    Many self-renewal-promoting factors of embryonic stem cells (ESCs) have been implicated in carcinogenesis, while little known about the genes that direct ESCs exit from pluripotency and regulate tumor development. Here, we show that the transcripts of Gadd45 family genes, including Gadd45a, Gadd45b, and Gadd45g, are gradually increased upon mouse ESC differentiation. Upregulation of Gadd45 members decreases cell proliferation and induces endodermal and trophectodermal lineages. In contrast, knockdown of Gadd45 genes can delay mouse ESC differentiation. Mechanistic studies reveal that Gadd45g activates MAPK signaling by increasing expression levels of the positive modulators of this pathway, such as Csf1r, Igf2, and Fgfr3. Therefore, inhibition of MAPK signaling with a MEK specific inhibitor is capable of eliminating the differentiation phenotype caused by Gadd45g upregulation. Meanwhile, GADD45G functions as a suppressor in human breast cancers. Enforced expression of GADD45G significantly inhibits tumor formation and breast cancer metastasis in mice through limitation of the propagation and invasion of breast cancer cells. These results not only expand our understanding of the regulatory network of ESCs, but also help people better treatment of cancers by manipulating the prodifferentiation candidates.